By the PharmaTradz BD Team. Published October 2026.
Six months after semaglutide's core patent expired on 20 March 2026, generic versions are on sale in several markets and the first lessons are clear. Prices reset within weeks, not years. Supply proved fragile in places. Regulators watched promotion closely. And in a number of big markets, an expired patent still did not mean an open market. Here is what that means if you import, distribute or tender for semaglutide.
Where things stand in October 2026
The 20 March date mattered because Novo Nordisk filed the core semaglutide patent family on 20 March 2006. Wherever no extension was granted, twenty years of protection ended that day. That covered India and China, among others. In the United States, the European Union, the United Kingdom and Japan, extensions push protection to around 2031–2032, so generics there are still years away.
Between those two groups sits a third: markets where the patent has gone but something else still blocks entry. China is the clearest case. As of early October, its regulator had approved no generic semaglutide, although between ten and twelve local applicants have filed. Novo says its data protection for the diabetes product runs to about April 2027, and at least one Chinese review was suspended in August. For a market-by-market view, see our guide to semaglutide patent expiry by country.
| Market | Position in October 2026 | What buyers should note |
|---|---|---|
| India | Generics on sale since 21 March 2026 from about a dozen manufacturers | Pens, reusable cartridges, multi-dose vials and prefilled syringes all available; close regulatory watch on promotion |
| Canada | First generic approved in April 2026 and in pharmacies from mid-May | Pricing rules push prices down as more generics are approved |
| Brazil | First approval in May 2026, several more since | Approvals so far are for type 2 diabetes |
| South Africa | First approval in July and first launch in August 2026 | More applications pending; early discounts are modest |
| China | Patent expired, no generic approved yet | Data protection to about April 2027; plan for 2027 at the earliest |
| US, EU, UK, Japan | Still protected | Generic entry expected from about 2031–2032 |
Lesson one: the price reset is fast and deep
India showed what a real generic market looks like. Within a month, generics held about half of semaglutide sales by value and roughly four in five injectable units. Monthly treatment with a generic multi-dose vial started at around ₹1,300, and generic pens sold at roughly ₹1,800 to ₹4,500 a month depending on format and strength. The originator did not stand still: from 1 April it cut the price of its starting dose to ₹1,415 a week.
For tender agencies and distributors, the practical point is that price references go stale quickly. A quotation built on last quarter's prices can be out of line within weeks of a new launch. It is worth asking suppliers for validity periods and for how they will handle a mid-contract price move.
Lesson two: the device matters as much as the molecule
Semaglutide is a weekly injection, so the delivery system is part of the product. In India, buyers can now choose between disposable pens, reusable pens with cartridges, multi-dose vials and single-shot prefilled syringes. Each has different implications for your registration file, your pharmacy or hospital users and your price.
- Pens are the format patients and prescribers know, but device patents can outlast the molecule patent. In Canada, pen-device patents are reported to run to at least 2033.
- Vials cost less and suit hospital or clinic use, but dosing relies on syringes and training.
- Prefilled syringes sit in between and need their own device documentation.
The oral tablet is a separate case. It depends on a formulation with an absorption enhancer that is covered by its own patents in several markets until around 2031, so treat tablet supply strictly case by case.
Lesson three: supply can stumble
Being first is not the same as being reliable. One of the first manufacturers approved in India paused supply in July after a problem with an active-ingredient batch and said it expected to resume by November. On the same day, another manufacturer recalled some pen batches. Neither event is unusual for a new, high-volume injectable scaled up at speed, but both left buyers looking for alternatives.
If you are building a semaglutide portfolio, ask early about where the active ingredient is made, whether there is a second source, how many commercial batches have been released, and what stability data exist for your climate zone. A supplier that answers these questions clearly is worth more than one whose price is a few per cent lower.
Lesson four: regulators are watching promotion and the supply chain
High demand brings grey-market and counterfeit risk, and regulators have responded. In March, India's drug regulator warned companies against direct or surrogate promotion of GLP-1 medicines. Within days, it inspected 49 entities and issued notices, and in May it asked state regulators to tighten checks on supply chains and advertising.
Expect the same attention in other markets as generics arrive. Work only with suppliers who hold the right manufacturing and export licences, keep batch traceability through to the end customer, and avoid any marketing that would read as consumer promotion of a prescription medicine. Our guide on how to verify pharma suppliers sets out the basic checks.
Lesson five: the cold chain is not optional
Unopened semaglutide pens and vials are stored refrigerated at 2–8 °C, and the in-use rules after first use differ by product, so always follow the approved label. That makes the shipping route, the temperature data loggers and the receiving warehouse part of your quality system, not an afterthought. If you are new to temperature-sensitive products, start with our explainer on the pharma cold chain.
What to ask a semaglutide supplier
Before you request prices, make sure the basics are in place. Semaglutide is supplied only to licensed importers, distributors, hospitals and tender agencies, against the registration or import permit your country requires. We do not supply patients directly.
| Ask for | Why it matters |
|---|---|
| Registration status in your market, or the route to it | Shows whether you can sell now or need a filing first |
| Dossier format (CTD or ACTD) and data on comparability with the reference product | Determines how long registration will take |
| Active-ingredient source and a second source, if any | Protects you against a single batch problem |
| Device type, device documentation and needle supply | The pen or syringe is part of what your regulator reviews |
| Stability data, including the climate zone of your market | Supports shelf life and storage claims |
| Cold-chain plan and temperature records | Required to show product quality on arrival |
| Certificate of analysis per batch, GMP certificate and a CoPP | Standard proof of quality and origin |
If your regulator accepts the ACTD rather than the CTD format, our comparison of CTD and ACTD explains the differences.
What to watch next
- China in 2027. With ten or more local applicants, approvals after data protection ends could change regional pricing quickly.
- The Gulf and Africa. Saudi Arabia saw its first generic launch in September 2026, and more applications are pending across the region.
- Weight-management indications. Many early approvals cover type 2 diabetes only. Watch for label extensions market by market.
- Price pressure on the originator. Early discounts in some markets are modest, so expect further price moves as more generics are approved.
How PharmaTradz can help
We work with licensed importers, distributors and tender agencies who need semaglutide or other GLP-1 medicines for markets where generics are legal and registered. We can help you compare manufacturers on documentation, device options and supply capacity, and support registration through our dossier licensing and registration service. To start, send us a sourcing request with the strength, presentation, target market and your licence status.
Brand names mentioned are trademarks of their owners and are used only to identify the medicine. Market information is as of 9 October 2026 and changes quickly; this article is not legal advice.
Frequently Asked Questions(FAQs)
Is generic semaglutide legal now?
It depends on the country. Generics are approved and on sale in markets such as India, Canada, Brazil, South Africa and Saudi Arabia. In the United States, the EU, the UK and Japan, semaglutide is still protected until about 2031–2032, and in China no generic has been approved yet.
When did the semaglutide patent expire?
The core patent expired on 20 March 2026 in countries where Novo Nordisk did not obtain an extension, including India and China. Where extensions apply, protection runs for several more years.
Why is there no generic semaglutide in China yet?
Although the patent has expired, regulatory data protection for the originator's diabetes product is reported to run to about April 2027. Around ten to twelve Chinese companies have applied, but none had been approved by early October 2026.
What forms does generic semaglutide come in?
Mainly weekly injections in disposable pens, reusable pens with cartridges, multi-dose vials and prefilled syringes. Oral tablets are covered by separate formulation patents in several markets, so their availability varies.
Who can buy semaglutide through PharmaTradz?
Only licensed importers, distributors, hospitals and tender agencies, against the registration or import permit their country requires. We do not supply patients directly.
